Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays

Picha, Lefkothea; Pakas, Ioannis; Guialis, Apostolia; Moutsopoulos, Haralampos Μ.; Vlachoyiannopoulos, Panayiotis G.

doi:10.1016/j.jaut.2008.07.001

Cited by 7 publications

(4 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date no marker constellation allows the identification of patients prone to this complication [41-43]. ACAs are frequently associated with other antibodies, such as anti-Ro [44-46], anti-mitochondrial (M2) [15,44,47,48] and anti-p25/p23 [31,49,50] antibodies. These associations were confirmed by this study.…”

Section: Resultsmentioning

confidence: 99%

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

et al. 2011

View full text Add to dashboard Cite

IntroductionIn the present study, we analysed in detail nuclear autoantibodies and their associations in systemic sclerosis (SSc) patients included in the German Network for Systemic Scleroderma Registry.MethodsSera of 863 patients were analysed according to a standardised protocol including immunofluorescence, immunoprecipitation, line immunoassay and immunodiffusion.ResultsAntinuclear antibodies (ANA) were detected in 94.2% of patients. In 81.6%, at least one of the autoantibodies highly associated with SSc or with overlap syndromes with scleroderma features was detected, that is, anti-centromere (35.9%) or anti-topoisomerase I (30.1%), followed in markedly lower frequency by antibodies to PM-Scl (4.9%), U1-ribonucleoprotein (U1-RNP) (4.8%), RNA polymerases (RNAPs) (3.8%), fibrillarin (1.4%), Ku (1.2%), aminoacyl-transfer RNA synthetases (0.5%), To (0.2%) and U11-RNP (0.1%). We found that the simultaneous presence of SSc-associated autoantibodies was rare (1.6%). Furthermore, additional autoantibodies were detected in 55.4% of the patients with SSc, of which anti-Ro/anti-La, anti-mitochondrial and anti-p25/p23 antibodies were most frequent. The coexistence of SSc-associated and other autoantibodies was common (43% of patients). SSc-associated autoantibodies disclosed characteristic associations with clinical features of patients, some of which were previously not acknowledged.ConclusionsThis study shows that five autoantigens (that is, centromere, topoisomerase I, PM-Scl, U1-RNP and RNAP) detected more than 95% of the known SSc-associated antibody responses in ANA-positive SSc patients and characterise around 79% of all SSc patients in a central European cohort. These data confirm and extend previous data underlining the central role of the determination of ANAs in defining the diagnosis, subset allocation and prognosis of SSc patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Characteristics of the 69 articles included in the metaanalysis are shown in Table 1. The studies incorporated data for SSc patients from different locations: North America 4,12,17,26,27,34,43,58,60,70,76,77 , South America 16,53 , Europe 10,11,14,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,47,48,49,50,51,52,57,59,…”

Section: Resultsmentioning

confidence: 99%

The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review

2013

View full text Add to dashboard Cite

show abstract

“…64,65 Autoantibodies Circulating AMAs are highly specific for PBC and are detected in nearly 100% of patients when tested for using techniques based on recombinant mitochondrial antigens (immunoblotting or enzymelinked immunosorbent assay). The high sensitivity and specificity of AMAs make them one of the most specific diagnostic tests of human immunopathology, 66 different from other autoimmune conditions, 67,68 including autoimmune hepatitis. 69 In most clinical settings for initial screening, AMAs are usually detected by indirect immunofluorescence using rodent liver, kidney and stomach sections as a substrate, leading in some cases to false positive or negative results.…”

Section: What Causes Liver Damage?mentioning

confidence: 99%

Experimental evidence on the immunopathogenesis of primary biliary cirrhosis

et al. 2009

View full text Add to dashboard Cite

Comparative qualitative and quantitative analysis of scleroderma (systemic sclerosis) serologic immunoassays

Cited by 7 publications

References 72 publications

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review

Experimental evidence on the immunopathogenesis of primary biliary cirrhosis

Contact Info

Product

Resources

About